-

Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in this target population.

“As a first-in-class, oral, small molecule inhibitor of PARP14, RBN-3143 has the potential to treat a range of inflammatory diseases, including but not limited to atopic dermatitis, asthma and ulcerative colitis. Following the successful completion of the single and multiple ascending dose assessment in healthy subjects to assess safety and pharmacokinetics, we are pleased to be advancing this study into patients with moderate-to-severe atopic dermatitis, the first therapeutic area of focus for the RBN-3143 program,” said Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “As a leading company focused on novel targets in the field of cellular stress response, the initiation of the atopic dermatitis portion of our Phase 1 study marks an important advancement in evaluating NAD+-utilizing enzymes as targets for inflammatory diseases.”

“In preclinical models, RBN-3143 suppresses markers of disease, demonstrating its potential as an oral alternative to biologics in a broad range of inflammatory diseases of the skin, lung and the gastrointestinal system,” said Sudha Parasuraman, M.D., Chief Medical Officer, Ribon Therapeutics. “RBN-3143 has demonstrated a favorable safety and pharmacokinetic profile in healthy subjects and we look forward to its evaluation in patients with moderate-to-severe atopic dermatitis and to demonstrate proof-of mechanism.”

About PARP14
PARP14 is a NAD+-utilizing monoART (mono-ADP-ribosyltransferase) controlling cell signaling and regulating protein function. PARP14 expression is elevated in tissues of various inflammatory diseases, but it is not highly expressed in normal tissues. Elevated PARP14 expression leads to higher levels of first order cytokines, specifically alarmins, and second order cytokines, Th2 and Th17 cytokines, in the inflammatory lesion, and ultimately the increase in disease tissue eosinophils and neutrophils which drive pathology.

About RBN-3143
RBN-3143, a first-in-class, oral small molecule inhibitor of PARP14, has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases. This is the second program emerging from the BEACON+ platform to enter clinical development. Selective inhibition of PARP14 leads to a decrease in alarmins and dampening of the IL-17 and IL-4/13 signaling pathways. Ribon has demonstrated efficacy in multiple preclinical models of inflammatory disease. RBN-3143 is currently being evaluated in a Phase 1 clinical study in healthy volunteers and atopic dermatitis patients.

About Ribon Therapeutics
Ribon Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. Ribon’s portfolio includes two oral, first-in-class clinical programs, RBN-2397 (a PARP7 inhibitor) and RBN-3143 (a PARP14 inhibitor), targeting broad indications in oncology and inflammatory diseases, respectively. The company explores novel areas of biology with the goal of developing effective treatments for patients with limited therapeutic options.

Leveraging its proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, Ribon is building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoARTs (mono-ADP-ribosyltransferase), which have applications across multiple therapeutic areas. Ribon is located in Cambridge, Massachusetts. For more information, visit https://ribontx.com/.

Contacts

Investors:
Brendan Burns
Argot Partners
212.600.1902
Ribon@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

Ribon Therapeutics


Release Versions

Contacts

Investors:
Brendan Burns
Argot Partners
212.600.1902
Ribon@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

More News From Ribon Therapeutics

Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced a $25 million investment from Pfizer. Ribon plans to use the proceeds to support clinical development of its potentially first-in-class oral small molecule programs in oncology (RBN-2397, a PARP7 inhibitor) and immunology (RBN-3143, a PARP14 inhibitor). As part of the investment, Robert Rickert, Ph.D., Senior Vice President and...

Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim. This includes a small molecule inhibitor designed to modulate intra- and extracellular CD38 activity, potentially restoring immune function in various diseases, as well as corresponding patents and other proprietary information. B...

Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced in a late-breaking presentation, compelling preclinical data for RBN-3143, a novel, orally administered, first-in-class inhibitor of PARP14 with potential in a range of inflammatory diseases. The data were presented in a late-breaking poster titled “The PARP14 Inhibitor RBN-3143 Suppresses Lung Inflammation in Preclinical Models...
Back to Newsroom